February 13, 2025
Lindis grants Pharmanovia rights to market and spearhead its launch across Europe
Lindis Biotech GmbH, a clinical stage biopharmaceutical company, and Pharmanovia, a global pharmaceutical company, announced Thursday that catumaxomab has received marketing authorisation from the European Commission (EC), making the drug the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.